Show simple item record

dc.contributor.authorRutherford, Matthew A
dc.contributor.authorScott, Jennifer
dc.contributor.authorKarabayas, Maira
dc.contributor.authorAntonelou, Marilina
dc.contributor.authorGopaluni, Seerapani
dc.contributor.authorGray, David
dc.contributor.authorBarrett, Joe
dc.contributor.authorBrix, Silke R
dc.contributor.authorDhaun, Neeraj
dc.contributor.authorMcAdoo, Stephen P
dc.contributor.authorSmith, Rona M
dc.contributor.authorGeddes, Colin C
dc.contributor.authorJayne, David
dc.contributor.authorLuqmani, Raashid
dc.contributor.authorSalama, Alan D
dc.contributor.authorLittle, Mark A
dc.contributor.authorBasu, Neil
dc.contributor.authorUK and Ireland Vasculitis Rare Disease Group (UKIVAS)
dc.date.accessioned2021-11-16T00:30:13Z
dc.date.available2021-11-16T00:30:13Z
dc.date.issued2021-09
dc.identifier.issn2326-5191
dc.identifier.urihttps://www.repository.cam.ac.uk/handle/1810/330648
dc.description.abstractOBJECTIVE: COVID-19 is a novel infectious disease with a broad spectrum of clinical severity. Patients with systemic vasculitis have an increased risk of serious infections and may be at risk of severe outcomes following COVID-19. We undertook this study to establish the risk factors for severe COVID-19 outcomes in these patients, including the impact of immunosuppressive therapies. METHODS: A multicenter cohort was developed through the participation of centers affiliated with national UK and Ireland vasculitis registries. Clinical characteristics and outcomes are described. Logistic regression was used to evaluate associations between potential risk factors and a severe COVID-19 outcome, defined as a requirement for advanced oxygen therapy, a requirement for invasive ventilation, or death. RESULTS: The cohort included 65 patients with systemic vasculitis who developed COVID-19 (median age 70 years, 49% women), of whom 25 patients (38%) experienced a severe outcome. Most patients (55 of 65 [85%]) had antineutrophil cytoplasmic antibody-associated vasculitis (AAV). Almost all patients required hospitalization (59 of 65 [91%]), 7 patients (11%) were admitted to intensive care, and 18 patients (28%) died. Background glucocorticoid therapy was associated with severe outcomes (adjusted odds ratio [OR] 3.7 [95% confidence interval 1.1-14.9]; P = 0.047), as was comorbid respiratory disease (adjusted OR 7.5 [95% confidence interval 1.9-38.2]; P = 0.006). Vasculitis disease activity and nonglucocorticoid immunosuppressive therapy were not associated with severe outcomes. CONCLUSION: In patients with systemic vasculitis, glucocorticoid use at presentation and comorbid respiratory disease were associated with severe outcomes in COVID-19. These data can inform clinical decision-making relating to the risk of severe COVID-19 in this vulnerable patient group.
dc.format.mediumPrint-Electronic
dc.languageeng
dc.publisherWiley
dc.rightsAttribution-NonCommercial 4.0 International
dc.rights.urihttps://creativecommons.org/licenses/by-nc/4.0/
dc.subjectUK and Ireland Vasculitis Rare Disease Group (UKIVAS)
dc.subjectHumans
dc.subjectRespiratory Tract Diseases
dc.subjectImmunosuppressive Agents
dc.subjectGlucocorticoids
dc.subjectRespiration, Artificial
dc.subjectHospitalization
dc.subjectOxygen Inhalation Therapy
dc.subjectSeverity of Illness Index
dc.subjectRegistries
dc.subjectOdds Ratio
dc.subjectRisk Factors
dc.subjectComorbidity
dc.subjectAged
dc.subjectMiddle Aged
dc.subjectIntensive Care Units
dc.subjectFemale
dc.subjectMale
dc.subjectSystemic Vasculitis
dc.subjectAnti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
dc.subjectCOVID-19
dc.subjectSARS-CoV-2
dc.titleRisk Factors for Severe Outcomes in Patients With Systemic Vasculitis and COVID-19: A Binational, Registry-Based Cohort Study.
dc.typeArticle
prism.endingPage1719
prism.issueIdentifier9
prism.publicationDate2021
prism.publicationNameArthritis Rheumatol
prism.startingPage1713
prism.volume73
dc.identifier.doi10.17863/CAM.78093
dcterms.dateAccepted2021-03-04
rioxxterms.versionofrecord10.1002/art.41728
rioxxterms.versionVoR
rioxxterms.licenseref.urihttp://www.rioxx.net/licenses/all-rights-reserved
rioxxterms.licenseref.startdate2021-09
dc.contributor.orcidRutherford, Matthew A [0000-0001-5626-2470]
dc.contributor.orcidAntonelou, Marilina [0000-0001-6653-7511]
dc.contributor.orcidGopaluni, Seerapani [0000-0002-1584-6186]
dc.contributor.orcidDhaun, Neeraj [0000-0001-9128-6603]
dc.contributor.orcidMcAdoo, Stephen P [0000-0001-8260-8770]
dc.contributor.orcidBasu, Neil [0000-0003-4246-3145]
dc.identifier.eissn2326-5205
rioxxterms.typeJournal Article/Review
cam.issuedOnline2021-07-27


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

Attribution-NonCommercial 4.0 International
Except where otherwise noted, this item's licence is described as Attribution-NonCommercial 4.0 International